Article
Another surprise from Metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy.
Molecular cancer therapeutics - 1 Dec 2013
Iglesias David A, Yates Melinda S, van der Hoeven Dharini, Rodkey Travis L, Zhang Qian, Co Ngai Na, Burzawa Jennifer, Chigurupati Sravanthi, Celestino Joseph, Bowser Jessica, Broaddus Russell, Hancock John F, Schmandt Rosemarie, Lu Karen H
Abstract excerpt
Metformin is an oral biguanide commonly used for the treatment of type II diabetes and has recently been demonstrated to possess antiproliferative properties that can be exploited for the prevention and treatment of a variety of cancers. The mechanisms underlying this effect have not been fully elucidated. Using both in vitro and in vivo models, we examined the effects of metformin on endometrial tumors with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.